Kodiak Sciences Inc
Kodiak Sciences Inc Stock, NASDAQ:KOD
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.